age
Item
men or women between 30-80 years of age inclusive at time of enrolment.
boolean
C0001779 (UMLS CUI [1])
non-independent diabetes mellitus
Item
patients who had non-independent diabetes mellitus (niddm) defined by the criteria of the national diabetes data group.
boolean
C0011849 (UMLS CUI [1])
sulphonylurea
Item
patients who had sulphonylurea therapy for at least 6 months and a constant dose for at least 2 months prior to visit 1.
boolean
C0038766 (UMLS CUI [1])
patients who had fasting plasma glucose <= 15.0 mmol/l at screening. hemoglobin a1c >= 7.5%.
Item
patients who had fasting plasma glucose <= 15.0 mmol/l at screening. hemoglobin a1c >= 7.5%.
boolean
C0202042 (UMLS CUI [1])
C0019018 (UMLS CUI [2])
contraceptive methods
Item
female patients must be (1) post-menopausal, i.e. > 6 months without menstrual period, surgically sterile, or (2) using hormonal contraceptives or intrauterine contraceptive devices. female patients who were taking hormonal contraceptives must also use an additional barrier form or intrauterine form of birth control.
boolean
C0700589 (UMLS CUI [1])
written informed consent
Item
patients who had given their written informed consent to participate.
boolean
C0021430 (UMLS CUI [1])
female patients who were pregnant, breast feeding or planning a pregnancy during the course of the study.
Item
female patients who were pregnant, breast feeding or planning a pregnancy during the course of the study.
boolean
C0032961 (UMLS CUI [1])
patients who had a fasting plasma glucose > 15.0 mmol/l at screening, or severity of diabetes mellitus requiring administration of insulin, or patients with ketonuria.
Item
patients who had a fasting plasma glucose > 15.0 mmol/l at screening, or severity of diabetes mellitus requiring administration of insulin, or patients with ketonuria.
boolean
C0202042 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
C0162275 (UMLS CUI [3])
renal or hepatic disease
Item
patients who had clinically significant renal or hepatic disease (i.e., patients with serum creatinine > 160 micromol/l (1.8 mg/dl); alt, ast, total bilirubin, gamma gt, or alkaline phosphatase more than 2.5 times the upper limit of the normal laboratory range).
boolean
C0201976 (UMLS CUI [1])
C1287351 (UMLS CUI [2])
any clinically significant abnormality identified on the screening physical examination, laboratory tests, electrocardiogram which in the judgment of the investigator would preclude safe completion of the study.
Item
any clinically significant abnormality identified on the screening physical examination, laboratory tests, electrocardiogram which in the judgment of the investigator would preclude safe completion of the study.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
leukocyte count < 3000/mm3 or platelet count <120,000/mm3
Item
patients who had leukocyte count < 3000/mm3 or platelet count <120,000/mm3.
boolean
C0023508 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
blood pressure
Item
systolic blood pressure >180mmhg or diastolic blood pressure >114mmhg while on appropriate hypertensive therapy.
boolean
C0005823 (UMLS CUI [1])
anemia or porphyria
Item
significant anemia (hemoglobin < 11 g/dl for males or < 10g/dl for females) or diagnosis of porphyria.
boolean
C0002871 (UMLS CUI [1])
C3463940 (UMLS CUI [2])
diabetic neuropathy
Item
symptomatic diabetic neuropathy of sufficient severity to require treatment for control of symptoms (eg, painful peripheral neuropathy, symptomatic orthostatic hypotension, urinary retention, gastric stasis, pedal ulcers).
boolean
C0011882 (UMLS CUI [1])
diabetic retinopathy
Item
diabetic retinopathy imminently requiring treatment for preserving or restoring vision.
boolean
C0011884 (UMLS CUI [1])
body mass index
Item
body mass index(bmi) < 22 and >38 kg/m2 (formula: bmi= weight, kg ÷height, m2)and variation in body weight of >=5% between screening and visit2.
boolean
C1305855 (UMLS CUI [1])